3 Things You Need to Know if You Buy Viking Therapeutics Today

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could see its shares soar for years.But that doesn't mean you should rush to buy the stock without understanding what else is going on with this stock and why it's making the changes it's making. Let's examine three things you'll need to factor into your decision if you plan on investing in Viking Therapeutics today.Biotech stocks tend to be catalyst-driven. When there's an event that provides new information about the company's chances of making profits down the line, like clinical trial data readouts, the market tends to reprice shares accordingly. And for Viking, there are a couple of big catalysts that are likely to occur within the next year, both of which pertain to its clinical readouts.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool